Searching for your content…
from 8 AM – 10 PM ET
FN Media Group Presents USA News Group News Commentary
News provided by
Jan 10, 2022, 11:54 ET
Share this article
VANCOUVER, BC, Jan. 10, 2022 /PRNewswire/ — USA News Group – Nearly 10% of the estimated ~1.9 million new cancer cases in the USA will be diagnosed as leukemia, lymphoma and myeloma. According to analysts at Markets and Markets, the leukemia therapeutics market is projected to reach US$17.1 billion by 2024, growing at a CAGR of 6.8%. Along the way, there have been several positive developments in the fight against blood cancers including more recent updates from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), AbbVie Inc. (NYSE:ABBV), Novartis AG (NYSE:NVS), Thermo Fisher Scientific Inc. (NYSE:TMO), and NeoGeonomics, Inc. (NASDAQ:NEO).
Through treatment with its flagship immunotherapeutic agent pelareorep, Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) recently announced preclinical data demonstrating the drug’s synergistic anti-leukemic effects when combined with the chemotherapeutic agent azacytidine.
"These compelling preclinical findings, together with previously reported data demonstrating clinical proof-of-concept in multiple myeloma, indicate that pelareorep’s immunotherapeutic effects extend across multiple hematological malignancies," said Thomas Heineman, M.D., Ph.D., Global Head of Clinical Development and Operations at Oncolytics. "They also further highlight pelareorep’s potential to enhance the efficacy of a wide range of cancer therapeutics and have stimulated interest in investigator-sponsored clinical studies of pelareorep in leukemia."
Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments, as indicated with these latest preclinical results.
Compared to either treatment alone, treatment with pelareorep plus azacitidine led to a statistically significant reduction (p<0.01) in tumor burden in a leukemia xenograft mouse model.
Compared to either treatment alone, treatment with pelareorep plus azacitidine led to a statistically significant (p<0.001) synergistic enhancement of anti-leukemic activity against AML cell lines, a benefit that was confirmed in AML patient samples in vitro.
The combination of pelareorep and azacitidine dramatically upregulated multiple genes known to drive anti-cancer immune responses such as IFNβ1, BATF2, IL-12β, CCL2, TLR3, and PD-L1.
The intravenously delivered pelareorep induces anti-cancer immune responses and promotes an inflamed tumor phenotype—turning "cold" tumors "hot"—through innate and adaptive immune responses to treat a variety of cancers.
Oncolytics is currently conducting and planning clinical trials evaluating pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies as it advances towards a registration study in metastatic breast cancer.
For certain leukemia patients, new research is confirming long remissions after treatment with the drug ibrutinib from AbbVie Inc. (NYSE:ABBV) along with chemotherapy.
The study involved 85 patients (all 65 or younger) with chronic lymphocytic leukemia (CLL), with 46 patients exhibiting more aggressive, unmutated IGHV subtype of the disease.
"Patients with lower-risk CLL, which is marked by mutated IGHV genes, can gain long remissions from a six-month regimen known as FCR – for the chemotherapy drugs fludarabine and cyclophosphamide and the antibody therapy rituximab," said Dr. Matthew Davids, of Dana-Farber Cancer Institute in Boston. "Our study examined whether a time-limited course of ibrutinib given in combination with FCR can provide lasting remissions for patients with CLL regardless of whether they have the IGHV-mutated or -unmutated subtype."
The study’s participants received ibrutinib for seven days, followed by a combination of ibrutinib and FCR for up to six months. They continued to receive ibrutinib alone for two more years, and stopped taking the drug when they had no detectable leukemia cells in their bone marrow after the two years.
Novartis AG (NYSE:NVS) is moving forward with its cancer development efforts, having recently shared positive results from two ongoing trials for lymphoma and leukemia.
During the company’s Phase III ASCEMBL study of Scemblix (asciminib) on patients diagnosed with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase, the drug showed that it was able to hold out longer before a follow up is needed compared to Bosulif (bosutinib).
In comparison, Scemblix delivered a major molecular response (MMR) rate of 29.3% at 48 weeks versus 13% for those who received Bosulif.
The findings at week 48 were consistent with a doubling of the drug’s efficacy at week 4, where it logged a 25% MMR against Bosulif’s 13%. In addition, patients experienced fewer adverse reactions in the Scemblix group at 7.1% versus 25%.
Novartis also announced that its candidate drug for relapsed or refractory follicular lymphoma (FL), Kymriah (tisagenlecleucel), showed strong efficacy during the follow-up around 17 months from the Phase II ELARA trial.
Researchers found that Kymriah delivered high rates of durable responses in the majority of high-risk disease subgroups who, otherwise, would have a poor diagnosis. Novartis already submitted applications for approval with EU and U.S. regulators in October. Once approved, the company will elevate its research to the real-world setting.
A leading provider of cancer-focused genetic testing services and global oncology contract research services providers NeoGeonomics, Inc. (NASDAQ:NEO) recently announced they will use the Ion Torrent Genexus System, from Thermo Fisher Scientific Inc. (NYSE:TMO).
The Ion Torrent Genexus System is the first turnkey next-generation sequencing (NGS) solution that automates the specimen-to-report workflow to deliver results in as little as a single day
"We have worked with Thermo Fisher Scientific in multiple genomic initiatives and are excited to leverage their Genexus System to deliver comprehensive genomic data with unprecedented speed," said Mark Mallon, CEO of NeoGenomics. "By compressing turnaround time for results from weeks to days we can ensure researchers have the data they need to accelerate progress as they look to develop critically needed myeloid cancer treatments in the future."
As part of the preclinical research investigation, NeoGenomics will receive early access to Thermo Fisher’s new Oncomine Myeloid Assay GX v2 to validate the assay on the Genexus System. The assay is designed to optimize variant detection, covering key genes and fusions across the myeloid cancer spectrum.
"Myeloid cancers such as acute myeloid leukemia present unique challenges due to their heterogeneity and sample complexity," said Garret Hampton, president of clinical sequencing and oncology, Thermo Fisher Scientific. "NGS allows researchers to profile all key mutations simultaneously, saving time compared to sequential single-gene testing. By combining the speed of the Genexus System with NeoGenomics‘ expertise and data services, we hope to advance discoveries that will inform future therapeutic development for patients who desperately need new treatment options."
For more information please visit: https://usanewsgroup.com/2020/02/24/why-biotechnology-companies-are-so-important/
USA News Group
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
USA News Group is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with USA News Group or any company mentioned herein. The commentary, views and opinions expressed in this release by USA News Group are solely those of USA News Group and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
SOURCE USA News Group
SOURCE USA News Group
More news releases in similar topics
Cision Distribution 888-776-0942
from 8 AM – 9 PM ET
New Developments in Fight Against Blood Cancers, in Leadup to US$17.1 Billion Market by 2024 – PRNewswire
Searching for your content…